TGFB1 and cancer: Different strategies such as ligand traps, antisense oligonucleotides (ASOs), small molecule receptor kinase inhibitors, and peptide aptamers have been successfully used to target and modulate TGF-β signaling in cancers in vitro, however these strategies have faced severe problems in clinical trial studies [9, 13–15].